Evidence map›Paper›PMID 34602076›Full record

ArticleLipids in health and disease2021

Negative correlation between endoglin levels and coronary atherosclerosis.

Haibin Chen, Yiping Wang, Bing Sun, Xunxia Bao, Yu Tang, Feifei Huang, Sibo Zhu, Jiahong Xu

Open access · goldAbstract read
In one paragraph

Article in Lipids in health and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Annals of translational medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Haibin ChenDepartment of Cardiovascular, Tongji Hospital, School of Medicine, Tongji University, No. 389, Xincun Road, Putuo District, 200065, Shanghai, China.
Yiping WangDepartment of Cardiovascular, Tongji Hospital, School of Medicine, Tongji University, No. 389, Xincun Road, Putuo District, 200065, Shanghai, China.
Bing SunDepartment of Cardiovascular, Tongji Hospital, School of Medicine, Tongji University, No. 389, Xincun Road, Putuo District, 200065, Shanghai, China.
Xunxia BaoSchool of Life Science, Anhui Medical University, Hefei, 230022, China.ORCID https://orcid.org/0000-0002-6085-7319
Yu TangDepartment of Cardiovascular, Tongji Hospital, School of Medicine, Tongji University, No. 389, Xincun Road, Putuo District, 200065, Shanghai, China.
Feifei HuangDepartment of Cardiovascular, Tongji Hospital, School of Medicine, Tongji University, No. 389, Xincun Road, Putuo District, 200065, Shanghai, China.
Sibo ZhuDepartment of Epidemiology, School of Public Health, State Key Laboratory of Genetic Engineering and Human Phenome Institute, School of Life Sciences, Fudan University, Songhu Road 2005, Shanghai, 200438, China. sibozhu@fudan.edu.cn.ORCID http://orcid.org/0000-0003-4800-8987
Jiahong XuDepartment of Cardiovascular, Tongji Hospital, School of Medicine, Tongji University, No. 389, Xincun Road, Putuo District, 200065, Shanghai, China. xujiahong@tongji.edu.cn.
Tongji University · CNAnhui Medical University · CNFudan University · CN

Funding

national natural science foundation of china 81500347
6 · The paper itself

Abstract

backgroundCoronary artery disease (CAD) is a common cardiovascular disease, and abnormal blood lipid metabolism is an important risk factor. Transforming growth factor-ß (TGF-ß) and its receptor (TGF-ßR) can inhibit the release of inflammatory factors through the SMAD pathway-mediated immune response, thereby suppressing the progression of CAD. Endoglin (TGF-ßRIII), a TGF-ßR family homologous receptor protein, is directly involved in the immunoregulatory process, but the exact mechanism is unclear. This study aimed to clarify the pathophysiological effects of endoglin on the development of atherosclerosis and to explore the mechanism of the signalling pathway.

methodsWe downloaded the GEO dataset to perform a functional analysis of SMAD family activity and TGF-ß receptor protein expression in the monocyte expression profiles of patients with familial hyperlipidaemia (FH). The effect of endoglin on endothelial cell proliferation, migration, and apoptosis was examined by disrupting the endoglin gene in human umbilical vein endothelial cells (HUVECs) and validated by western blotting. The related genes and pathways regulated by endoglin were obtained by analysing the sequencing data.

resultsResearch has shown that interference with endoglin can promote the proliferation and migration and significantly inhibit the apoptosis of vascular endothelial cells. Interference with endoglin particularly encourages the expression of VEGFB in vascular endothelial cells.

conclusionThe endoglin gene in vascular endothelial cells regulates the PI3K-Akt, Wnt, TNF, and cellular metabolism pathways by activating the SMAD pathway. RAB26, MR1, CCL2, SLC29A4, IBTK, VEGFB, and GOLGA8B play critical roles. Endoglin interacts closely with 11 proteins such as CCL2 and SEPRINE1, which participate in the vital pathway of plaque formation. Interference with endoglin can alter the course of coronary atherosclerosis.

Indexed as

Signal TransductionApoptosisCell ProliferationCoronary Artery DiseaseEndoglinEndothelium, VascularGene Expression ProfilingGene Expression RegulationHumansHuman Umbilical Vein Endothelial CellsHyperlipidemiasSequence Analysis, RNAEndoglinAtherosclerosisCoronary artery diseaseDrug targetsEndoglinEndothelial dysfunctionGenetic interferenceHyperlipidaemia

Identifiers

PMID34602076
PMCPMC8487532
OpenAlexW3203663669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.